$1.15
0.021.77%
Last update: Nov 11, 11:46 AM
Palisade Bio Inc
PALINASDAQ
Palisade Bio fell 37.9% from $1.82 to $1.13, behind the S&P 500's +9.8%. Its worst day was Dec 3 (−19.9%), and its low came Nov 2 at $1.12.
Nov 11, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Palisade Bio shares rose 14.4%, while the S&P 500 fell 0.0%.
+14.4% · S&P 500 0.0%
Palisade Bio shares fell 19.9%, while the S&P 500 rose 0.1%.
−19.9%, the year's worst day · S&P 500 +0.1%
Story events cover the past 12 months · Times ET
Palisade Bio shares fell 16.0%, while the S&P 500 rose 0.7%.
−16.0% · S&P 500 +0.7%
EPS of $1.08 beat the $-0.04 estimate on $0.00 revenue.
+1.1% · S&P 500 +1.1%
Palisade Bio closed at its highest level of the year, 53.8% above where the year started.
+12.0% · S&P 500 −0.7%
EPS of $-0.05 missed the $-0.04 estimate on $0.00 revenue.
−2.6% · S&P 500 +0.6%
ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and EuropeFirst patient enrollment anticipated in the second half of 2026; primary efficacy
+18.0%, the year's best day · S&P 500 +1.6%
EPS of $-0.05 beat the $-0.05 estimate on $500,000.00 revenue.
+1.9% · S&P 500 −0.3%
Palisade Bio shares fell 16.1%, while the S&P 500 fell 0.4%.
−16.1% · S&P 500 −0.4%
Palisade Bio closed at its lowest level of the year, 38.5% below where the year started.
−3.4% · S&P 500 −0.5%
Where it ended: a close of $1.13 on Nov 10, 2026.
Nothing in the past 12 months.
All PALI dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for PALI and SPY from Benzinga historical bars. Not investment advice.
